November 5, 2025 — Leads & Copy — Cybin Inc.’s Chief Business Officer, George Tziras, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, November 10-12, 2025. The chat will be webcast live on Monday, November 10, 2025, at 4:30 p.m. ET, and archived on Cybin’s investor relations website.
Cybin, a Phase 3 clinical-stage neuropsychiatry company, is committed to revolutionizing mental healthcare through novel drugs that provide effective and durable results for patients. The company is currently developing CYB003, a deuterated psilocin analog, in Phase 3 studies for major depressive disorder and CYB004, a deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.
Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland.
George Tziras, Cybin’s Chief Business Officer
